Vertex HIV Drug Candidate Development Halted by GlaxoSmithKline Because of Formulation Problem
December 22, 2006
GlaxoSmithKline has stopped collaborating with Vertex Pharmaceuticals Inc. on the HIV drug candidate brecanavir (VX-385), Vertex said in a recent Securities and Exchange Commission filing. The drug, which was in mid-stage clinical testing, would be too difficult to formulate, said Glaxo. The firms have collaborated since 1993, yielding the HIV treatments Agenerase and Lexiva.